Sign inJoin waitlistJoin the waitlist

Jordyn Griffin

Fellowship Associate Program Director · Virginia Commonwealth University Health System

Credentials: · · · · ·

History

Virginia Commonwealth University Health System Fellowship
Present
Virginia Commonwealth University Health System
Present

Pediatric Hematology/Oncology
Indiana University School of Medicine
2016–2019
Internal Medicine-Pediatrics
University of Kentucky College of Medicine
2012–2013
Medical College of Georgia
2006–2010

Research

When Multiple Objective Measures of Medication Adherence Indicate Incongruent Adherence Results: An Example with Pediatric Cancer
International Journal of Environmental Research and Public Health · 2020 · 4 citations
Right on Schedule: Improving the Rate of Clinic Appointments Scheduled Prior to Hospital Hospital Discharge
Pediatric Quality and Safety · 2022 · 1 citations

Caitlin Cain
1 paper
Emily Mueller
1 paper
EI
Evrosina Isaac
1 paper
Jennifer Rohan
1 paper
Kerry Hege
1 paper
Mahvish Rahim
1 paper · 1 as a fellow
Tanvi Verma
1 paper · 1 as a resident

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031